Search clinical trials for: BMS-188667

Total 1992 results

Cancer Institute and Hospital, Chinese Academy...

Completed

FSRT Combined With TMZ for Large BMs: a PSM Study

Chemotherapy | Brain Metastases | Radiotherapy
Bristol-Myers Squibb

Terminated

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Hypercholesterolemia

Germany, Canada
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

Sarcoma

United States
Universidad de Murcia

Unknown

The Efficacy of Melatonin in the Burning Mouth Syndrome (BMS)

Sleep Disorders, Circadian Rhythm

Spain
Bristol-Myers Squibb

Terminated

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

Septic Shock | Severe Sepsis

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Infection, Human Immunodeficiency Virus

United Kingdom
Bristol-Myers Squibb

Terminated

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Leukemia

France, United States, Spain, Poland, Finland, Argentina, Canada, Belgium
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Bristol-Myers Squibb

Completed

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Venous Thrombosis | Pulmonary Embolism

United States, Argentina, Canada, Mexico, Puerto Rico, Israel, Australia, Poland, Denmark
Bristol-Myers Squibb

Active, not recruiting

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Neoplasms by Site

United States, Australia, Denmark, France, Switzerland, Austria, Canada, Germany, Japan, Netherlands, Norway, Spain, United Kingdom, Finland, Italy
National Cancer Institute (NCI)

Terminated

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2)

Head and Neck Squamous Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Malignant Solid Tumor

United States, France, Italy, Australia, Canada, Germany, Netherlands
Bristol-Myers Squibb

Active, not recruiting

Trial of BMS-986012 in Combination With Platinum and Etoposide

Small Cell Lung Cancer

Spain
Bristol-Myers Squibb

Completed

Effect of BMS-986165 on the Blood Levels of Metformin

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Hepatitis C Virus

France, Spain, United Kingdom, United States, Germany, Italy, Argentina, Ireland
National Cancer Institute (NCI)

Terminated

BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
National Cancer Institute (NCI)

Terminated

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Extrahepatic Bile Duct Cancer | Localized Gallbladder Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent... and other conditions

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Switch Study of BMS-337039 in Schizophrenic Out-patients

Schizophrenia

Belgium, Spain, Italy, Austria, Germany, France, Czech Republic, United Kingdom, Greece, Hungary
Louisiana State University Health Sciences Center...
Bristol-Myers Squibb

Terminated

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

Schizophrenia | Schizoaffective Disorder

United States
Bristol-Myers Squibb

Completed

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Tumors

Japan
Bristol-Myers Squibb

Completed

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Carcinoma, Hepatocellular

United States, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Advanced Solid Tumors

United States, Canada, United Kingdom
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Bristol-Myers Squibb

Completed

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (FALCON 2)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD) | Hepatic Cirrhosis

United States, Japan
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Ipilimumab + Temozolomide in Metastatic Melanoma

Metastatic Melanoma

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Melanoma | Non-Small Cell Lung Cancer | Advanced Cancer

Canada, United States, Australia, France, Italy, Spain, Finland, Germany, Norway, Poland, Sweden
Incyte Corporation

Terminated

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Solid Tumors

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Bristol-Myers Squibb

Not yet recruiting

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy

Korea, Republic of
Bristol-Myers Squibb

Completed

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Melanoma

Germany, Italy, Sweden, United Kingdom, Belgium, Netherlands, Spain, Finland, Austria, Ireland, Poland, Portugal, Russian Federation, Switzerland, Czechia, Greece, Hungary, Luxembourg, Norway, Romania
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
RWTH Aachen University

Withdrawn

The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)

Cirrhosis of the Liver | Re-stenosis
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Advanced Solid Tumors

United States, Chile, Argentina, Belgium, Canada, Japan, Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Advanced Cancer

United States, Belgium, Canada
Bristol-Myers Squibb

Recruiting

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Netherlands, France, Italy, Belgium
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Esophageal Squamous Cell Carcinoma

United Kingdom
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Withdrawn

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen (QUATTROTURBO)

Hepatitis C Virus Genotype 4 Infection

France
Biosensors Europe SA
European Cardiovascular Research Center

Unknown

A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free)

Bleeding | Stable Angina | In-stent Coronary Artery Restenosis | Ischemic Heart Disease Silent | ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction

Switzerland
Celgene

Recruiting

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Lymphoma

Japan
Bristol-Myers Squibb

Terminated

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Hepatocellular Carcinoma

Canada, Singapore, Korea, Republic of, Taiwan
R-Pharm

Completed

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

Neoplasms | Advanced Solid Tumors

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD)

United States, Japan
Bristol-Myers Squibb

Terminated

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

Gastrointestinal Neoplasms

United States
Bristol-Myers Squibb

Completed

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Breast Cancer | Solid Tumor

United States
Bristol-Myers Squibb

Completed

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Drug-Drug Interaction Study in Healthy Subjects

Hepatitis C

United States

Search clinical trials for: BMS-188667

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations